BCDA - BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

• BioCardia ( NASDAQ: BCDA ) signed an agreement to provide its catheter biotherapeutic delivery product candidates for BlueRock Therapeutics' cell therapy products to treat heart failure.
• Under the agreement, BioCardia will receive an upfront payment, a portion of which is creditable for biotherapeutic delivery products and support services.
• The agreement has an option to negotiate for a non-exclusive worldwide license to BioCardia biotherapeutic delivery product candidates for certain cell types for cardiac indications and is time limited, the company said in an Aug. 24 press release.
• "We look forward to working with BlueRock to deliver their therapeutic candidates locally to the heart. Our having a role in their world class well-funded development effort is aligned with our mission to develop and enhance therapies to treat cardiovascular and pulmonary disease," said BioCardia President and CEO Peter Altman.
• BCDA +5.83% to $2.18 premarket Aug. 24

For further details see: